{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:18:18Z","timestamp":1792081098707,"version":"4.4.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Epidemiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a malignant hematologic disorder characterized by the abnormal clonal proliferation of bone marrow plasma cells and excessive production of immunoglobulins, often leading to severe organ damage. Due to its high incidence, recurrence, and death rates, MM poses a significant burden on individuals and global healthcare systems. This study leverages the latest data from the Global Burden of Disease Study 2021 (GBD 2021) to analyze the epidemiological trends of MM and propose effective preventive strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from GBD 2021, we analyzed the age-standardized incidence rate (ASIR), death rate (ASDR), and disability-adjusted life years (DALYs) of MM, evaluating temporal trends through estimated annual percentage change (EAPC). Pearson correlation analysis was employed to explore the relationship between age-standardized rates (ASRs) and the Sociodemographic Index (SDI). Additionally, frontier analysis was conducted. Finally, Bayesian age-period-cohort models were utilized to predict the trends of MM ASRs through 2040.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2021, the global number of new MM cases was 148,755 (95% UI: 131,780.4\u2013162,049.2), with 116,359.6 deaths (95% UI: 103,078.6\u2013128,470.6) and 2,595,595 DALYs (95% UI: 2,270,483.6\u20132,889,968.2). Age-standardized rates increased with age. Between 1990 and 2021, the global burden of MM exhibited a consistent upward trend across all populations, with males and older adults bearing the highest burden. The analysis demonstrated a positive correlation between ASRs and the SDI. Frontier analysis indicated regions with medium-to-high SDI have the greatest potential for reducing ASRs. Among all risk factors, high body mass index (BMI) was identified as the most significant contributor to MM. Projections suggest that by 2040, the global burden of MM may experience a decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Driven by population aging and advancements in diagnostic capabilities, the global burden of multiple myeloma continues to rise. Targeted prevention and treatment strategies, particularly for elderly and high-risk populations, are essential to alleviate the disease burden and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fepid.2025.1568688","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T01:24:32Z","timestamp":1745889872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Global, regional, and national burden of multiple myeloma from 1990 to 2021 and projections for 2040: a systematic analysis for the global burden of disease 2021 study"],"prefix":"10.3389","volume":"5","author":[{"given":"Yuying","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/cam4.1347","article-title":"Epidemiology of multiple myeloma in 17 Latin American countries: an update","volume":"7","author":"Curado","year":"2018","journal-title":"Cancer Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"217440","DOI":"10.1016\/j.canlet.2025.217440","article-title":"The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050","volume":"611","author":"Dou","year":"2025","journal-title":"Cancer Lett"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S0140-6736(20)30977-6","article-title":"Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950\u20132019: a comprehensive demographic analysis for the global burden of disease study 2019","volume":"396","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1476853","article-title":"Global, regional, and national burdens of osteoarthritis from 1990 to 2021: findings from the 2021 global burden of disease study","volume":"11","author":"Li","year":"2024","journal-title":"Front Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0284391","DOI":"10.1371\/journal.pone.0284391","article-title":"Estimating the potato farming efficiency: a comparative study between stochastic frontier analysis and data envelopment analysis","volume":"18","author":"Sultana","year":"2023","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e009584","DOI":"10.1136\/bmjopen-2015-009584","article-title":"Incidence of multiple myeloma in Great Britain, Sweden, and Malmo, Sweden: the impact of differences in case ascertainment on observed incidence trends","volume":"6","author":"Velez","year":"2016","journal-title":"BMJ Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e39698","DOI":"10.1016\/j.heliyon.2024.e39698","article-title":"A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia","volume":"10","author":"Chng","year":"2024","journal-title":"Heliyon"},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.46989\/001c.92555","article-title":"Epidemiology, treatment trends, and outcomes of multiple Myeloma in the Middle East and Africa: a systematic review","volume":"6","author":"Mattar","year":"2024","journal-title":"Clin Hematol Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-021-00088-3","article-title":"Are African primary physicians suspicious enough? Challenges of multiple myeloma diagnosis in Africa","volume":"33","author":"Thokerunga","year":"2021","journal-title":"Egypt J Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2023.04.003","article-title":"Obesity and multiple myeloma: emerging mechanisms and perspectives","volume":"92","author":"Tentolouris","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1611338","DOI":"10.3389\/pore.2023.1611338","article-title":"Obesity as a risk factor for multiple myeloma: insight on the role of adipokines","volume":"29","author":"Tie","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2013viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41416-024-02723-6","article-title":"Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features","volume":"131","author":"Arnold","year":"2024","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/1055-9965.EPI-16-0762-T","article-title":"Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the international multiple myeloma consortium (IMMC)","volume":"26","author":"Birmann","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41416-018-0010-4","article-title":"Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts","volume":"118","author":"Marinac","year":"2018","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fonc.2018.00103","article-title":"The relation of obesity-related hormonal and cytokine levels with multiple myeloma and non-hodgkin lymphoma","volume":"8","author":"Hosgood","year":"2018","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1038\/s41598-024-54193-8","article-title":"Diet-induced obesity reduces bone marrow T and B cells and promotes tumor progression in a transplantable Vk*MYC model of multiple myeloma","volume":"14","author":"Nedal","year":"2024","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"108007","DOI":"10.1016\/j.pharmthera.2021.108007","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma","volume":"232","author":"Choi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"Br Med J"}],"container-title":["Frontiers in Epidemiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2025.1568688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T01:24:34Z","timestamp":1745889874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2025.1568688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":32,"alternative-id":["10.3389\/fepid.2025.1568688"],"URL":"https:\/\/doi.org\/10.3389\/fepid.2025.1568688","relation":{},"ISSN":["2674-1199"],"issn-type":[{"value":"2674-1199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"article-number":"1568688"}}